Find an expert

Wendy Goodwin is a registered veterinarian in Queensland and has worked for the University of Queensland as a clinical anesthetist since 2010. She received her veterinary degree from the University of Queensland in 2004 and in 2013 was awarded a Doctorate of Philosophy by the University of Queensland for her research thesis ‘Studies of Alfaxalone in Horses’. In 2008 she was awarded Membership of the Australian & New Zealand College of Veterinary Scientists in Equine Medicine and in 2013 was awarded Membership in Veterinary Anaesthesia and Critical Care. In 2016 Wendy sucessfully became a Fellowship of the Australian & New Zealand College of Veterinary Scientists in Veterinary Anaesthesia and Critical Care.

Wendy is passionate about veterinary anaesthesia and analgesia and has dedicated the majority of her professional career to pursuing excellence in this field. Her clinical anaesthetic experience has covered a wide range of species including horses, small animal companion animals, farm animals, avian and exotic animals and animals used in scientific research. Wendy has a strong research interest and is keen to further explore research and development opportunities in the veterinary and medical sectors. She has papers published in peer reviewed scientific journals and presented her research findings at international conferences relating to veterinary anaesthesia and pain management.

Dr. Richard Gordon leads a multi-disciplinary, industry-partnered research program in Translational Neuroscience which integrates immunology, drug development, pharmacology, metabolomics and microbial metagenomics. His group aims to understand and therapeutically target key pathological mechanisms which drive the onset and progression of neurodegenerative disorders such as Parkinson’s disease (PD) and Amyotrophic Lateral Sclerosis (ALS). Their work combines target validation studies in human patients with mechanistic insights from disease models to develop and test novel therapeutic strategies that can be translated towards clinical trials.

Key research themes within this program include:

• Understanding how chronic immune and inflammasome activation contribute to neurodegeneration in the CNS
• The role of gut dysbiosis and gastrointestinal dysfunction in Parkinson’s disease pathophysiology
• Therapeutic targeting of the gut-brain axis for neuroprotection
• Drug discovery, development and repositioning for novel therapeutic targets
• Discovery and validation of clinical biomarkers for PD and ALS
• Clinical trials for disease-modifying therapeutic strategies

I am a Research Fellow and Leader in Pain Relief Innovation at AIBN, UQ. My research interests sit at the interface of drug delivery and the pain field. My overarching research goal is to improve the quality of day to day life of patients suffering from chronic pain, by applying nanotechnology to the development of novel highly effective pain-killer products for improving chronic pain management. I am looking for highly motivated postgraduate students.

I also enjoy volunteering within the academic community, most notably as Head of the SBMS ECR Committee and Treasurer for The Queensland Chinese Association of Scientists and Engineers (QCASE). I am currently serving as guest editor of Pain Research and Management.and JoVE Methods Collection.

Research Interests

My research is focusing on nano-based drug formulation and development to improve chronic pain management. I have a broad and unique background in both pharmacology and drug delivery systems, with specific expertise in the development of novel drug products and testing their analgesic efficacy and safety including pharmacokinetic and pharmacodynamic studies. To date, I have established five different techniques to produce painkiller–loaded nanoparticles and nanofibers aimed at improving pain relief for patients where currently available pain-killers either lack efficacy or produce dose-limiting side-effects. For example, there is a small and very potent peptide that has been on the market as a chemical for over 10 years but which cannot be used as a therapeutic due to its short half-life and poor oral bioavailability. In the form of my nanoparticles, that peptide has the potential to become an oral treatment for improving pain management in patients whose pain is currently poorly alleviated by clinically used pain-killers. I have significant expertise in the use of rodent pain models to assess novel analgesics, and I have received excellent training in conducting research in accordance with the stringent requirements of the Quality Management System (quality accreditations (GLP and ISO17025) from NATA). Together, my knowledge, skills and experience will facilitate the efficient translation of my research from the bench to the clinic.

The current focus of the lab is on the development of drug-products to solve one of the largest unmet medical needs in the pain field through use of sustainable materials. 1) We are developing multifunctional sutures including biodegradable pain relief sutures. 2) We are developing my innovative novel nanoparticles, which deliver innate-immune targeting peptides for the treatment of cancer and cancer-related pain. We are establishing a platform for the development of safe, effective delivery for other small molecule peptide drugs in general to pave their way to clinical trials. 3) Our research also investigates the role of C5a and C3a, estrogen, etc. in the pathogenesis of chronic pain including neuropathic pain, cancer-related pain, low back pain and OA pain.

We work in collaboration with other leading Australian and international researchers to stay at the forefront of the drug delivery systems field and the pain field. We also provide preclinical evaluation of novel compounds and formulations.

Senior Research Fellow

Room 7048, Level 7, Pharmacy Australia Centre of Excellence Phone:+61 7 334-61898; Fax: +61 7 334-61999 Email: a.hewavitharana@pharmacy.uq.edu.au

Amitha obtained her B.Sc. from the University of Colombo (Sri Lanka), M.Sc. from the university of Victoria (B.C., Canada) and PhD in analytical chemistry from the University of Alberta (Canada). Following that, she held brief research positions at the Massey University (New Zealand) and NZ Leather Research Institute. She then held a research scientist position at the NZ Dairy Research Institute (NZDRI, currently Fonterra Research) for 4 years before moving to Australia in 1997.

In Australia, she commenced her career as a lecturer in analytical chemistry at the University of Western Sydney, and then at Queensland University of Technology (QUT) until 2001. Following that, she held research positions in CSIRO (food science) and in QHSS (investigative chemistry) before joining the school of pharmacy in 2004.

I am an academic and consultant working in global health with a focus on health technology assessment (HTA), health systems and services research, and the use of medicines in populations. I have a particular interest in the use of data and research for evidence-informed decision making and implementation science in the context of low and middle income countries, especially in sub-Saharan Africa. I have worked on international health projects in Indonesia and am currently working on several projects in HTA and medicines use in Ghana and sub-Saharan Africa. I work with an extensive network of clinicians and health professionals to investigate the use of medicines and adverse effects in general practice, cancer, psychiatry, neurology, and internal medicine. I have honorary or visiting appointments at the University of Queensland (UQ, Brisbane, Australia), Imperial College London (UK, International Decision Support Initiative) and Kwame Nkrumah University of Science and Technology (KNUST, Kumasi, Ghana). I have a BSc(Hons) and MPH from UQ and a PhD from Monash University. I have lived or worked in Australia (Brisbane, Melbourne), Canada (Toronto), Indonesia (Yogyakarta), UK (London), and Ghana (Accra, Kumasi). I worked as a consultant in HTA in Australia for many years evaluating submissions to subsidise medicines on the Pharmaceutical Benefits Scheme (PBS). I am an experienced teacher having coordinated courses, lectured, and tutored in undergraduate and postgraduate programs. I was a Foundation Coordinator in the UQ Master of Pharmaceutical Industry Practice (from 2019). I am an advisor on diverse PhD and student research projects.

I am a medicinal chemist, and my research focuses on developing chemical modification strategies to enhance the drug-like properties of bioactive peptides, modulating protein-protein interactions, and designing chemical tools to explore biological mechanisms.

Dr Lee is a mid-career researcher with training in neuroscience, and additional experience in pharmacology and immunity. He completed his Ph.D. at the University of Queensland (UQ) in 2014 and continued his post-doctoral research studies in neuroinflammation and neurodegenerative diseases. He is currently a Senior Research Fellow and Group Leader at UQ's School of Biomedical Sciences, where he focusses on innate immune and inflammatory pathways including the complement system and inflammasomes in motor neuron disease (amyotrophic lateral sclerosis), Huntington’s disease, and Parkinson’s disease. Dr Lee’s research has demonstrated the therapeutic potential of multiple anti-inflammatory drugs targeting innate immune-mediated neuroinflammation to reduce neuronal cell death in animal models of neurodegenerative disease. He is also interested in the links between the immune system, stress response, and energy metabolism in neurodegeneration.

Dr. Joan Li is a Senior Lecturer and a Research Fellow with an established national and international reputation at The University of Queensland. She holds both an MD and a PhD, blending clinical and scientific expertise, which provides her with a unique perspective on research and education. While establishing an emerging profile in medical education, she maintains engagement in discipline-related biomedical research through collaboration and supervision.

With over seven years of teaching experience, Joan has actively engaged in face-to-face teaching in biomedical science and medicine courses, contributed to curriculum design, development, and course coordination for both undergraduate and postgraduate programs. She brings her strong analytical skills and critical thinking abilities, honed through her medical and biomedical research background, to her teaching practices. Driven by a genuine passion for teaching, Joan continuously strives for excellence, with specific interests in assessment, curriculum design, development and student learning experience. She has implemented innovative teaching methods, designed diverse and inclusive curricula, created new learning activities, and fostered student engagement as learning partners, with a consistent goal of improving curriculum quality and enhancing student learning outcomes.

Leveraging her medical knowledge, extensive experience in biomedical research, and growing understanding of medical education, Joan is committed to developing medical students into critical thinkers and lifelong learners with a genuine appreciation for medical practice and medical research, enabling them to better serve an ever-changing society. Drawing upon her extensive experience in developmental biology and physiology, particularly in cardiac and renal research, Joan actively supervises higher degree research students and continues to make significant contributions to discipline-related research through publications and collaborations.

Dr. Joan Li is a versatile academic professional with a rich background in biomedical research and an emerging presence in medical education research. Her dedication to teaching and learning, combined with her impressive track record in both disciplines, makes her a valuable asset to The University of Queensland and the broader academic community.

Junxian Lim is an accomplished molecular biologist at the Institute for Molecular Bioscience. With a strong background in cell biology, protein biochemistry, and pharmacology, he has established himself in the field. Collaborating with researchers at universities, institutions, as well as international industry partners like AstraZeneca and Sosei Heptares, he has contributed significantly to advancing scientific knowledge.

Throughout his doctoral studies, Junxian authored seven ground-breaking studies focused on the development of novel bioactive inhibitors targeting immune cells and inflammatory diseases. These contributions have paved the way for innovative approaches to drug development. Utilizing his expertise, he has successfully developed and characterized a diverse range of protein and cellular assays that enable in-depth investigations into immunity and inflammation. His research findings have been published in prestigious scientific journals, including Nature Communications, Cell Reports, Journal of the American Chemical Society, Diabetes, Journal of Medicinal Chemistry, and the British Journal of Pharmacology. His work has been highly cited, reflecting its impact and significance within the scientific community.

Recognized for his outstanding mentoring abilities, Junxian has supervised or co-supervised the research of two completed PhD students, six completed MPhil students, and three completed Honours students. The success of his former students is a testament to his dedication and guidance. They continue to excel and actively contribute to research endeavours around the world, spanning countries such as Australia, Singapore, Korea, India, Japan, and China.

Beyond his research and mentoring achievements, Junxian actively participates in the scientific community. He serves on the editorial boards of esteemed journals like Journal of Translational Medicine, Frontiers in Molecular Biosciences and Biology. This involvement allows him to stay at the forefront of scientific advancements and contribute to the dissemination of knowledge within his field.

Prof Lipman is Executive Director of the Burns Trauma & Critical Care Research Centre; Professor of Anesthesiology & Critical Care, The University of Queensland and until recently (for 23 years) was Director of Department of Intensive Care Medicine, Royal Brisbane and Women's Hospital; He holds Honorary Professorial appointments at Chinese University of Hong Kong, Unversity of Witwatersrand (South Africa) and Qeensland University of Technology.

He has qualifications in anesthesia and intensive care and has set up and been in charge of a number of Intensive Care and Trauma Units in South Africa before coming to Australia in 1997. he currently manages a large multidisciplinary research team with an output of over 120 peer-reviewed articles per annum. He has supervised dozens of PhD students to completion and is currently supervising 6 PhD, 1 MPhil and 1 MBBS/Hons students. Prof Lipman has been instrumental in developing the anaesthesiology and critical care component of a graduate medical program for Queensland and continues to lecture to medical and postgraduate students.

Prof Lipman is the author of over 550 peer reviewed publications, 30 book chapters and has been invited to deliver over 120 lectures at national and international conferences in many countries across the world. His research interests include all aspects of infection management in intensive care and he has a special interest in the pharmacokinetics of antibiotic dosage, an area in which he received his MD in 2006. His research into antibiotic usage in acute situations has received international recognition and he is regarded as an expert in the field. As such, he and his research team have conducted and presently conduct a number of clinical trials in Australia, New Zealand, Hong Kong, Europe and the UK.

Prof Lipman is an Editorial Board member for 10 International Journals, is Section Editor on four Antibiotic related Journals, reviews for 23 journals and is an external reviewer for NHMRC project grants (Local) as well as equivalent for a number overseas countries.

He is Chief Investigator on a 7000 patient International Randomised Controlled Trial comparing bolus dosing versus continuous infusions of meropenem and piperacillin-tazobactam

Dr Liu is a research fellow with more than 15 years of experience in the field of pharmacometrics. She specialises in population pharmacokinetic modelling and provides popPK analysis and dosing simulation support for various projects in Centre of Research Excellence RESPOND

Transporters for Catecholamines and Serotonin. Science Education.

The overall theme of Lesley Lluka's research over 3 decades has been the structure and function of the noradrenaline transporter (NET) and the serotonin transporter (SERT). These transporters are important sites of action of drugs such as antidepressants.

More recently, Lesley Lluka's work has increasingly moved to Science Education, with a focus on areas such as student engagement in practical classes, innovative assessment practices to drive deep learning, and internationalization of the curriculum.

Over 5 years of experience in translational biomedical research, specialising in monoclonal antibody-based therapies, immuno-oncology, target discovery and theranostics in cancer. My main research focus is on targeted cancer therapies, understanding how target receptor endocytosis affects antibody drug conjugate (ADC) and radioligand therapy delivery, immune-mediated ADCC, and how combination therapies with immune checkpoint inhibitors can potentially improve therapeutic outcomes for patients.